Shares of Geron doubled this morning after the company posted an abstract of promising results from a small study at the Mayo Clinic conducted on imetelstat for myelofibrosis.
After more than a year of not-so-secret negotiations, Geron has finally auctioned off its long-stalled embryonic stem cell pipeline, handing it over to a newly created BioTime subsidiary in exchange for shares.
John Scarlett's plan to reinvent Geron as a developer of new and exciting cancer drugs has slammed into a fresh debacle.
The Menlo Park, CA-based biotech and BioTime inked a letter of intent, which outlines some of the terms for a BioTime subsidiary to take over Geron's embryonic stem cell programs that were shelved last year as Geron narrowed its focus to cancer drug development.
Back in early 2011 Geron CEO Thomas Okarma was forced to step aside as the biotech prepared to bring in a new CEO to restructure the operations. Now Okarma is back, leading a new regenerative medicine venture set up by BioTime. And he wants his stem cell work back.
Just 10 months after new Geron CEO John Scarlett dumped a decade's worth of stem cell work in favor of a special focus on cancer drugs, the biotech has written off a pair of lead drug studies after tracking discouraging progression-free survival data in Phase II.
Geron jumped in trading on Thursday after a report in Seeking Alpha about the biotech company's potential to have a breakout year with its experimental cancer drugs. Some investors swoon for volatile biotech stocks with the potential for major gains, and the Menlo Park, CA-based outfit's shares were up about 15% yesterday and traded at around $2 per share.
Twenty years after stem cell research seemed poised to change the world with the possibility of curing a wide range of diseases, and then struggled in fits and starts amid scientific and political obstacles, it is clearly morphing into new areas.
Drug developers have long dreamed of discovering a tonic to trip up the aging process, hunting for genetic clues and compounds that could provide a fountain of youth. U.K. researchers say they have...
GlaxoSmithKline ($GSK) has grabbed rights to biotech startup Angiochem's early-stage program for treating a lysosomal storage disease. The deal comes as the London-based drug giant and its large...